AR116052A2 - Forma cristalina de clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol - Google Patents

Forma cristalina de clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol

Info

Publication number
AR116052A2
AR116052A2 ARP190102495A ARP190102495A AR116052A2 AR 116052 A2 AR116052 A2 AR 116052A2 AR P190102495 A ARP190102495 A AR P190102495A AR P190102495 A ARP190102495 A AR P190102495A AR 116052 A2 AR116052 A2 AR 116052A2
Authority
AR
Argentina
Prior art keywords
methylpropyl
dimethylamino
ethyl
crystalline form
phenol hydrochloride
Prior art date
Application number
ARP190102495A
Other languages
English (en)
Inventor
Dagmar Lischke
Michael Gruss
Helmut Buschmann
Andreas Fischer
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34925507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR116052(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of AR116052A2 publication Critical patent/AR116052A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se relaciona con una forma cristalina de clorhidrato de (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol, métodos para su preparación y uso, y composiciones farmacéuticas que la contienen.
ARP190102495A 2004-06-28 2019-09-02 Forma cristalina de clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol AR116052A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04015091A EP1612203B1 (en) 2004-06-28 2004-06-28 Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

Publications (1)

Publication Number Publication Date
AR116052A2 true AR116052A2 (es) 2021-03-25

Family

ID=34925507

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050102663A AR049949A1 (es) 2004-06-28 2005-06-28 Forma cristalina de clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol
ARP190102495A AR116052A2 (es) 2004-06-28 2019-09-02 Forma cristalina de clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP050102663A AR049949A1 (es) 2004-06-28 2005-06-28 Forma cristalina de clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol

Country Status (27)

Country Link
US (16) US20070213405A1 (es)
EP (2) EP1612203B1 (es)
JP (1) JP4990764B2 (es)
KR (1) KR101096501B1 (es)
CN (1) CN1997621B (es)
AR (2) AR049949A1 (es)
AT (2) ATE368639T1 (es)
AU (1) AU2005256512B2 (es)
BR (2) BRPI0512792A (es)
CA (1) CA2572147C (es)
CY (2) CY1106929T1 (es)
DE (2) DE602004007905T2 (es)
DK (2) DK1612203T3 (es)
EC (1) ECSP17046065A (es)
ES (2) ES2291780T3 (es)
HR (1) HRP20110050T8 (es)
IL (1) IL180373A (es)
MX (1) MXPA06014741A (es)
NO (3) NO338605B1 (es)
NZ (1) NZ551605A (es)
PE (1) PE20060372A1 (es)
PL (2) PL1612203T3 (es)
PT (2) PT1612203E (es)
RU (1) RU2423345C2 (es)
SI (2) SI1612203T1 (es)
WO (1) WO2006000441A2 (es)
ZA (1) ZA200700774B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DK1612203T3 (da) * 2004-06-28 2007-12-03 Gruenenthal Gmbh Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
ES2623413T3 (es) * 2007-12-07 2017-07-11 Grünenthal GmbH Modificaciones cristalinas de (1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)fenol
EP2249811A1 (en) 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
EP2273983B1 (en) 2008-05-09 2016-07-20 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
PL2456424T3 (pl) 2009-07-22 2013-12-31 Gruenenthal Gmbh Stabilizowana przed utlenianiem odporna na naruszenie postać dawkowania
PL2456427T3 (pl) 2009-07-22 2015-07-31 Gruenenthal Gmbh Wytłaczana na gorąco postać dawki o kontrolowanym uwalnianiu
US8288592B2 (en) 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
US20130116333A1 (en) 2010-05-05 2013-05-09 Ratiopharm Gmbh Solid tapentadol in non-crystalline form
KR102146233B1 (ko) 2010-07-23 2020-08-21 그뤼넨탈 게엠베하 ３-(３-디메틸아미노-１-에틸-２-메틸-프로필)-페놀의 염 또는 공결정
AU2011297901B2 (en) 2010-09-02 2014-07-31 Grunenthal Gmbh Tamper resistant dosage form comprising inorganic salt
MX2013002293A (es) 2010-09-02 2013-05-09 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico.
WO2012051246A1 (en) 2010-10-12 2012-04-19 Ratiopharm Gmbh Tapentadol hydrobromide and crystalline forms thereof
PT2680832T (pt) 2011-03-04 2019-10-28 Gruenenthal Gmbh Formulação farmacêutica aquosa de tapentadol para administração oral
RS56692B1 (sr) 2011-03-04 2018-03-30 Gruenenthal Gmbh Polučvrsta vodena farmaceutska kompozicija koja sadrži tapentadol
HUE027514T2 (en) * 2011-03-04 2016-10-28 Gruenenthal Gmbh Parenteral administration of tapentadol
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
PE20141638A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
WO2013111161A2 (en) * 2012-01-10 2013-08-01 Msn Laboratories Limited Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof
WO2013120466A1 (en) 2012-02-17 2013-08-22 Zentiva, K.S. A new solid form of tapentadol and a method of its preparation
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
EA201401139A1 (ru) 2012-04-18 2015-03-31 Грюненталь Гмбх Устойчивая к разрушению и к сбросу дозы фармацевтическая лекарственная форма
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CZ304576B6 (cs) * 2012-07-24 2014-07-16 Zentiva, K.S. Oxalát TAPENTADOLU a způsob jeho přípravy
CN102924303B (zh) * 2012-10-31 2013-11-20 合肥市新星医药化工有限公司 盐酸他喷他多晶型c及其制备方法和应用
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
US9599565B1 (en) * 2013-10-02 2017-03-21 Ondax, Inc. Identification and analysis of materials and molecular structures
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
CZ307492B6 (cs) 2014-02-04 2018-10-17 Zentiva, K.S. Pevná forma maleátu tapentadolu a způsob její přípravy
GB2523089A (en) * 2014-02-12 2015-08-19 Azad Pharmaceutical Ingredients Ag Stable polymorph form B of tapentadol hydrochloride
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
PT3479823T (pt) 2015-03-27 2020-09-29 Gruenenthal Gmbh Formulação estável para administração parentérica de tapentadol
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
PL3445742T3 (pl) 2016-04-19 2020-05-18 Ratiopharm Gmbh Krystaliczny fosforan tapentadolu
MX2019003257A (es) 2016-09-23 2019-06-10 Gruenenthal Gmbh Formulacion estable para la administracion parenteral de tapentadol.
EP3585370A1 (en) 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic
US11492342B2 (en) 2020-11-03 2022-11-08 Landos Biopharma, Inc. Crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridin-2yl)methanone)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
EP1283203A1 (en) * 1996-08-14 2003-02-12 G.D. Searle & Co. Crystalline form of 4-(5-methyl-3-phenylisoxazol-4-yl) benzene-sulfonamide
JP4180368B2 (ja) * 2000-10-31 2008-11-12 サンド・アクチエンゲゼルシヤフト 塩酸ベンラファキシンの結晶形
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
EP1426355B1 (en) * 2001-09-13 2008-10-15 Kissei Pharmaceutical Co., Ltd. Crystals of hydroxynorephedrine derivative
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
DK1612203T3 (da) * 2004-06-28 2007-12-03 Gruenenthal Gmbh Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid

Also Published As

Publication number Publication date
DE602004007905T2 (de) 2008-05-08
JP2008504326A (ja) 2008-02-14
US20110294898A1 (en) 2011-12-01
US20140296346A1 (en) 2014-10-02
NO338605B1 (no) 2016-09-12
US20200385334A1 (en) 2020-12-10
CY1106929T1 (el) 2012-09-26
SI1799633T1 (sl) 2011-05-31
EP1799633B1 (en) 2011-01-19
IL180373A (en) 2012-05-31
ATE496021T1 (de) 2011-02-15
ES2291780T3 (es) 2008-03-01
WO2006000441A3 (en) 2006-05-04
IL180373A0 (en) 2007-06-03
KR101096501B1 (ko) 2011-12-20
AR049949A1 (es) 2006-09-20
BR122018014454B1 (pt) 2019-09-03
NO20171103A1 (no) 2007-01-24
JP4990764B2 (ja) 2012-08-01
BRPI0512792A (pt) 2008-04-08
DK1799633T3 (da) 2011-03-28
AU2005256512B2 (en) 2011-05-19
EP1612203A1 (en) 2006-01-04
NZ551605A (en) 2010-01-29
DE602004007905D1 (de) 2007-09-13
PL1799633T3 (pl) 2011-06-30
US20210261492A1 (en) 2021-08-26
US20180230082A1 (en) 2018-08-16
US20160122287A1 (en) 2016-05-05
EP1799633A2 (en) 2007-06-27
MXPA06014741A (es) 2007-02-12
SI1612203T1 (sl) 2007-12-31
PT1612203E (pt) 2007-08-20
KR20070039929A (ko) 2007-04-13
PT1799633E (pt) 2011-03-07
CA2572147C (en) 2012-10-30
ES2359504T3 (es) 2011-05-24
US20140011886A1 (en) 2014-01-09
US20200102261A1 (en) 2020-04-02
NO343922B1 (no) 2019-07-08
PL1612203T3 (pl) 2007-12-31
HRP20110050T8 (en) 2011-03-31
NO341239B1 (no) 2017-09-25
CN1997621B (zh) 2011-06-15
AU2005256512A1 (en) 2006-01-05
NO20070162L (no) 2007-01-24
US20190062263A1 (en) 2019-02-28
US20120302643A1 (en) 2012-11-29
US20100160447A1 (en) 2010-06-24
NO20160914A1 (no) 2007-01-24
US7994364B2 (en) 2011-08-09
US20070213405A1 (en) 2007-09-13
BR122018014454B8 (pt) 2021-07-27
EP1612203B1 (en) 2007-08-01
US20090186947A1 (en) 2009-07-23
CA2572147A1 (en) 2006-01-05
CY1111530T1 (el) 2015-08-05
HRP20110050T1 (hr) 2011-02-28
RU2423345C2 (ru) 2011-07-10
ATE368639T1 (de) 2007-08-15
DE602005026031D1 (de) 2011-03-03
ECSP17046065A (es) 2018-11-30
WO2006000441A2 (en) 2006-01-05
RU2007103297A (ru) 2008-08-10
PE20060372A1 (es) 2006-05-08
US20170166515A1 (en) 2017-06-15
US20230174458A1 (en) 2023-06-08
ZA200700774B (en) 2008-09-25
US20180029976A1 (en) 2018-02-01
CN1997621A (zh) 2007-07-11
DK1612203T3 (da) 2007-12-03

Similar Documents

Publication Publication Date Title
AR116052A2 (es) Forma cristalina de clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol
NO20171811A1 (no) Fremgangsmåte for fremstilling av (1R,2R)-3-(3-dimetylamino-1-etyl-2-metyl-propyl)-fenol
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
DK1786403T3 (da) Mod misbrug sikret, oral indgivelsesform indeholdende (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
CL2009001766A1 (es) Composicion farmaceutica solida para administracion oral que comprende: un taxano sustancialmente amorfo definido, un portador hidrofilico definido y un tensoactivo definido; metodo para preparar la composicion; y su uso para tratar una enfermedad neoplasica.
CR8717A (es) Nuevos compuestos
BRPI0607423A2 (pt) forma microcristalina de um composto, processo para a preparação da mesma, uso de uma forma microcristalina, composição farmacêutica e processo para a preparação da mesma, e, produto
ITMI20041820A1 (it) Composizione in micro-pellets a rilascio controllato di sostanze fisiologicamente attive, procedimento di preparazione e relativo impiego nel settore zootecnico.
CL2007003100A1 (es) Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
BRPI0808034A2 (pt) Método para produzir hidrocloreto de prasugrel, hidrocloreto de prasugrel, composição farmacêutica, e, uso de um hidrocloreto de prasugrel.
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
HN2006029142A (es) Proceso
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
BRPI0516464B8 (pt) método para a preparação de um produto farmacêutico
NO20074676L (no) Krystallinske former av (1 RS, 3RS, 6RS)-6-dimetylaminometyl-1-(3-metoksy-fenyl)cykloheksan-1,3-diol hydroklorid
BRPI0702869A2 (pt) formas cristalinas da o-desmetilvenlafaxina
BRPI0823286A2 (pt) Dois tipos de formas cristalinas de pinocembrina, sua preparação e seu uso para a fabricação de composições farmacêuticas.